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Original Contribution
Nitrated fibrinogen is a biomarker of oxidative stress in
venous thromboembolism
Marissa Martinez, Adam Cuker, Angela Mills, Richard Lightfoot, Yiying Fan,
W.H. Wilson Tang, Stanley L. Hazen, Harry Ischiropoulos
Introduction
Venous thromboembolism (VTE) is a common thrombotic 
disease that encompasses both deep vein thrombosis (DVT) and 
pulmonary embolism (PE). VTE affects around 1 per 1000 people 
per year within the United States, with increasing incidence for 
congenital and acquired thrombophilic risk factors [1 3]. VTE is a 
chronic disease with 30% of patients experiencing a recurrent 
event over 10 years [4,5] and is estimated to account for between 
100,000 and 180,000 deaths each year [6]. Thus, VTE represents a 
significant health problem that requires considerable attention.
The precise molecular and biochemical mechanisms of throm 
bus initiation in VTE remain unclear. Virchow proposed that 
changes in blood rheology, induction of a hypercoagulable 
state, or endothelial injury are conditions required for venous 
thrombosis [7]. More recent studies indicate that inflammation
plays an important role in VTE. However, the interplay between 
inflammation and Virchow’s triad is still unresolved. One possi 
bility is that components of the triad activate or damage 
endothelial cells within the vein wall resulting in upregulation 
of receptors for inflammatory and procoagulant molecules. Elec 
tron micrographs of early thrombus formation show leukocyte 
adhesion to the vein wall [8], presumably through the binding of 
P and E selectins that are expressed on activated endothelial 
cells [9,10]. Leukocytes shed tissue factor bearing microparticles, 
which induce coagulation and the production of a fibrin clot [11]. 
Neutrophils and monocytes, two of the most prevalent leukocytes 
in venous thrombi, are also able to generate nitrating intermedi 
ates, capable of lipid peroxidation and nitration of proteins 
[12,13].
One protein known to be modified by tyrosine nitration is the 
coagulant protein fibrinogen. Upon activation of the coagulation 
cascade, circulating plasma fibrinogen is cleaved by thrombin to 
fibrin monomers, which polymerize to form a fibrin clot. Recent 
studies demonstrate an emerging role for nitrated fibrinogen that 
links inflammation and oxidant production to coagulation.
Nitrated fibrinogen is elevated in the plasma of patients with
coronary artery disease (CAD) and in smokers [14,15]. Addition
ally, in humans injected with small amounts of lipopolysacchar
ide, plasma levels of nitrated fibrinogen increase and remain
elevated for at least 72 h postinjection [16]. This increase follows
an elevation of circulating myeloperoxidase, an enzyme localized
to the azurophilic granules of neutrophils, which is released
during neutrophil activation and is capable of generating nitrating
intermediates [12]. Although these data suggest that nitrated
fibrinogen plays a key role linking inflammation, oxidant produc
tion, and arterial thrombotic diseases, its role in VTE remains
undefined.
Moreover, nitrated fibrinogen is not simply a marker of
inflammation and oxidative stress, but also has functional effects
on fibrinogen and fibrin clotting. Fibrinogen nitration was shown
to increase the rate of fibrin clot formation, diminish clot lysis
rate, and alter fibrin clot structural and viscoelastic properties
[14 16]. These functional effects suggest that nitrated fibrinogen
may represent a risk factor for increased thrombotic tendency
during inflammation and oxidant stress. However, the levels of
nitrated fibrinogen in VTE have not been ascertained. Herein we
quantified the levels of nitrated fibrinogen in patients presenting
to the emergency department with suspected VTE and evaluated
if nitrated fibrinogen is a biochemical risk factor that could
explain associations of oxidative stress and inflammation with
thrombotic complications in VTE.
Materials and methods
Patient population
We performed a prospective cohort study from January 2010
to March 2011 of consecutive subjects 18 years of age or older
presenting to the Hospital of the University of Pennsylvania
emergency department with suspected acute lower extremity
DVT or PE. Exclusion criteria included history of VTE within the
prior 4 weeks, unavailable for 90 day follow up, and inability to
provide informed consent. DVT was diagnosed by compression
ultrasonography and PE by computed tomographic pulmonary
angiography. Patients with negative imaging were contacted by
telephone 90 days after enrollment to confirm that they did not
develop clinically apparent VTE. Those who reported develop
ment of VTE over this interval despite negative imaging were also
considered positive for DVT and/or PE. Secondary variables were
also collected, including demographic information, thrombotic
risk factors, comorbidities, and medications. Before initiation of
anticoagulant therapy in the emergency department, blood was
collected from patients in 3.2% sodium citrate (BD Vacutainer;
Franklin Lakes, NJ, USA). Blood was centrifuged at 150g for
15 min, and the supernatant, platelet rich plasma, was trans
ferred to a new tube. Platelet rich plasma was then centrifuged at
10,000g for 10 min to obtain platelet poor plasma, followed by
storage at 80 1C for future analysis. Study design was approved
by the Institutional Review Board Involving Human Subjects at
the University of Pennsylvania and written informed consent was
obtained from all study participants.
Plasma nitrated fibrinogen levels
Nitrated fibrinogen levels were measured in plasma using an
ELISA described previously [16]. Briefly, 96 well plates were
coated with 10 mg/ml anti nitrotyrosine antibodies generated
and described elsewhere [17] in 50 mM carbonate buffer, pH 9,
and incubated at 4 1C under constant rocking overnight. The next
day, the plates were washed with 50 mM Tris, 150 mM NaCl,
0.05% Tween 20 (TBS T). The plates were blocked with 3% bovine
serum albumin (BSA; Roche Diagnostics, Mannheim, Germany)
(wt/vol) in TBS T for 2 h at 37 1C, followed by incubation with 1%
BSA in TBS T for 1 h at 37 1C. A standard curve was created from
purified fibrinogen (American Diagnostica, Stamford, CT, USA)
that had been chemically nitrated and the levels of nitration were
independently determined [16]. Plasma samples were diluted
(1:10, 1:20) in 1% BSA in TBS T, added to the plate in duplicate,
and incubated 2 h at room temperature under constant rocking.
Plates were washed with TBS T and coated with 0.3 mg/ml horse
radish peroxidase (HRP) conjugated rabbit anti human fibrinogen
polyclonal antibody (DakoCytomation, Glostrup, Denmark) in 1%
BSA in TBS T. After 2 h incubation at room temperature under
gentle rocking, the plates were washed with TBS T and developed
with TMB substrate (KPL, Gaithersburg, MD, USA) followed by
quenching of the reaction with 2 M sulfuric acid (Fisher Scientific,
Fair Lawn, NJ, USA). The absorbance was measured at 405 nm
(Molecular Devices, Sunnyvale, CA, USA). Nitrated fibrinogen
values were normalized to quality control plasma run with each
plate. Each patient sample was analyzed a minimum of three
times and samples that exceeded 15% coefficient of variation were
excluded from analysis. The normalized mean intra assay and
interassay variations were 8.23 and 9.32%.
Plasma fibrinogen level
Fibrinogen levels were measured in plasma using an ELISA
previously described [16]. Ninety six well plates (Maxisorb;
Nunc, Rochester, NY, USA) were coated with 10 mg/ml mouse
anti fibrinogen monoclonal antibody [16] in carbonate buffer,
pH 9, and incubated at 4 1C, rocking overnight. The next day,
the plates were washed with TBS T and blocked with 3% BSA in
TBS T for 2 h at 37 1C. A standard curve was created from purified
fibrinogen (American Diagnostica) in TBS T. Plasma was diluted
(1:5000, 1:10,000), added to the plate in triplicate, and incubated
for 1 h at 37 1C. The plates were washed with TBS T, then coated
with 0.3 mg/ml HRP conjugated rabbit anti human fibrinogen
polyclonal antibody (DakoCytomation) in 1% BSA in TBS T, and
incubated 1 h at room temperature. The plate was developed with
the TMB peroxidase substrate as described above. Fibrinogen
values were normalized to quality control plasma run with each
plate. The normalized mean intra assay and interassay variations
were 11.23 and 14.0%.
Plasma fibrinogen levels were measured by the Clauss method
[18] using a Destiny Max coagulation analyzer according to the
manufacturer’s protocol (Trinity Biotech, County Wicklow,
Ireland).
D dimer
Plasma D dimer levels were measured at the University of
Pennsylvania Hospital Coagulation Laboratory using the Vidas
D dimer exclusion assay (bioMe´rieux, Lyon, France). This assay
measures the fibrin degradation product (FDP) D dimer by an
enzyme linked fluorescence assay. This sandwich ELISA based
method uses two anti FDP monoclonal antibodies (P10B5E12C9
and P2C5A10) coupled with fluorescence detection [19,20]. In
accordance with the manufacturer’s instructions, a D dimer level
of o0.5 mg/ml was considered negative.
The laboratory personnel and technologists performing all
assays were blinded to patient outcome. Laboratory results
obtained on the archived plasma samples were not made avail
able to clinicians or patients.
Statistics
Gaussian distribution was tested for all continuous variables
using a D’Agostino and Pearson omnibus normality test, which
indicated nonparametric distributions for all variables within our
data. Thus, comparisons between groups were made using the
Mann Whitney U test. Nitrated fibrinogen, D dimer, and fibrinogen
are given as the mean and the 95% confidence interval (CI). The
adjusted model for nitrated fibrinogen levels was created using the
generalized linear model, which accounted for demographics, comor
bidities, and VTE risk factors. Odds ratios were compared by Fisher’s
exact test. Trends in nitrated fibrinogen levels by quartile were
compared by w2 analysis. A P value o0.05 was considered statisti
cally significant. All statistical calculations were generated and
analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA,
USA) or R Statistical package (http://www.r project.org/).
Results
Patient characteristics
A total of 251 patients were enrolled in this study. Of the 83
subjects with suspected DVT, 18 had a positive ultrasound and an
additional 3 were determined to be positive on 90 day follow up.
Among the 168 subjects with suspected PE, 28 had a positive
computed tomographic pulmonary angiography and 1 additional
patient was found to have new PE at 90 days. Patient demo
graphics, disease history, risk factors, and medications are shown
in Table 1. Three well accepted risk factors for VTE were more
prevalent in the VTE positive subset: advanced age, active cancer,
and surgery within the past 6 weeks. VTE positive patients were
significantly older compared with negative patients and were
more likely to have active cancer or recent surgery. Thrombophi
lia testing was not performed as part of the study. Nevertheless,
3 patients reported a history of hereditary thrombophilia, includ
ing 1 with protein C and 2 with protein S deficiency. Additionally,
2 patients reported having antiphospholipid syndrome. No other
measured demographic variables, comorbidities, risk factors, or
medication use differed between VTE positive and VTE negative
patients (Table 1).
Fibrinogen levels in VTE patients
Fibrinogen levels were quantified by ELISA, which measures
fibrinogen antigen, and the Clauss assay, which measures fibrin
clotting time. The mean levels of fibrinogen compared by Mann
Whitney U test were not different between subjects with and
without VTE by either Clauss assay or by ELISA (Fig. 1A). Fibrino
gen levels were also similar between DVT and PE patients
irrespective of the assay employed (Clauss: DVT, n¼17, 3.8 mg/ml,
95% CI 3.0 4.6; PE, n¼27, 4.5 mg/ml, 95% CI 3.6 5.4. ELISA: DVT,
n¼21, 5.5 mg/ml, 95% CI 4.4 6.5; PE, n¼28, 5.6 mg/ml, 95%
CI 4.7 6.5; Fig. 1A). ELISA determined fibrinogen levels were
higher than those reported by Clauss assay, which is consistent
with findings in previous studies [21].
Nitrated fibrinogen levels in VTE patients
Nitrated fibrinogen was measured by an ELISA as described
previously [16]. The levels of nitrated fibrinogen were interpo
lated from a standard curve created with purified fibrinogen that
was chemically nitrated, and levels of nitration were indepen
dently determined [16]. To ensure the integrity of each assay,
every 96 well plate included a quality control plasma standard,
and intra and interassay variation did not exceed 15%. The mean
levels of nitrated fibrinogen were significantly higher in VTE
positive compared to VTE negative patients (Fig. 1B). Nitrated
fibrinogen levels were not different between DVT and PE patients
(DVT, n¼17, 60.9 nM, 95% CI 52.3 69.6; PE, n¼27, 63.9 nM, 95%
CI 55.2 72.5).
Previous data indicated that one functional effect of fibrinogen
tyrosine nitration was increased rate of fibrin formation. Because
the Clauss assay relies on fibrin clotting time in plasma to assess
fibrinogen levels, Spearman correlation analysis was used to
evaluate the relationship between nitrated fibrinogen and fibri
nogen levels (Fig. 1C). Nitrated fibrinogen correlated linearly with
Clauss measured fibrinogen levels (n¼207, r¼0.31, 95% CI 0.18 0.40;
Po0.0001).
D dimer levels in VTE patients
D dimers are fibrin degradation products that are produced in
response to clot lysis by plasmin and are used as a diagnostic
marker for VTE [19,22 25]. D dimer was measured with the Vidas
D dimer exclusion assay according to the manufacturer’s instruc
tions. As expected, mean D dimer levels were significantly higher
in VTE positive versus VTE negative patients (Fig. 1D).
Odds ratio for venous thromboembolism across increasing nitrated
fibrinogen levels
Cubic spline curves with 95% CI (n¼226) were constructed to
illustrate the relationship between nitrated fibrinogen levels and
Table 1
Characteristics of VTE patient population.
Non-VTE (n 201) VTE (n 50) P value
Age (years) 47.6716.7 53.3716.4 0.0206a
Gender (% male) 63 (31.3%) 23 (46.0%)
BMI (kg/m2) 31.479.2 28.976.7
Race and ethnicity
Caucasian 75 (37.3%) 26 (52.0%)
African American 121 (60.2%) 22 (44.0%)
Other 5 (2.5%) 2 (4.0%)
Hispanic 6 (3.0%) 2 (4.0%)
Disease history and risk factors
H/O DVT 35 (17.4%) 9 (18.0%)
H/O PE 28 (13.9%) 7 (14.0%)
H/O CAD/MI/angina 15 (8.2%) 5 (6.8%)
H/O stroke 15 (7.5%) 4 (8.0%)
Liver disease 9 (4.5%) 2 (4.0%)
Lupus 8 (4.0%) 0 (0.0%)
Rheumatoid arthritis 4 (2.0%) 1 (2.0%)
Peripheral artery disease 5 (2.5%) 4 (8.0%)
Active cancer 38 (18.9%) 19 (38.0%) 0.0075b
Recent surgeryc 26 (12.9%) 15 (30.0%) 0.0089b
Immobilization 4 6 weeks 30 (14.9%) 11 (22.0%)
Air travelc 4 (2.0%) 2 (4.0%)
Tobacco use 77 (38.3%) 17 (34.0%)
Pregnancy 5 (2.5%) 4 (8.0%)
Trauma 11 (5.5%) 3 (6.0%)
Infection 19 (9.5%) 5 (10.0%)
Medication
Antiplatelet 32 (15.9%) 8 (16.0%)
Anticoagulant 25 (12.4%) 8 (16.0%)
Statins 36 (17.9%) 11 (22.0%)
Hormonal contraception 9 (4.5%) 4 (8.0%)
Hormone therapy 1 (0.5%) 1 (2.0%)
Antioxidants 6 (3.0%) 3 (6.0%)
Immunosuppressants 29 (14.4%) 4 (8.0%)
Values shown are means7SD or the number and percentage of the sample group.
VTE composition: DVT, n 21; PE, n 29.
a Age and BMI were compared by Mann–Whitney U test.
b All other variables were compared by Fischer’s exact test.
c Within past 6 weeks.
the odds ratio of clinically documented VTE (Fig. 2). This analysis
shows a strong association between nitrated fibrinogen levels and
increased risk for VTE (Po0.005). A similar relationship was
found for rates of VTE across increasing nitrated fibrinogen
quartiles (w2 for trend 7.69; Po0.01; Table 2). Patients in the
highest quartile were compared with those in the lowest quartile
and were found to have an increased risk of VTE (Table 2). This
risk was maintained after univariate adjustment for the risk
factors found to be elevated in our VTE positive patient popula
tion: advanced age, active cancer, and recent surgery (Table 2,
Models 1, 2, and 3). However, multivariate analysis with these
risk factors did not reach statistical significance (Table 2, Model
4). This may reflect the small size of our VTE positive patient
population, in that additional adjustments reduce the final sam
ple size and eliminate statistical significance.
Discussion
Previous studies have implied that inflammation and oxidative
processes may be mechanistically linked to the pathogenesis of
VTE [12 16,26 31]. Nitration of proteins and, specifically,
nitrated fibrinogen have been quantified in the plasma of subjects
who experience inflammatory changes and oxidative burden
[14 16]. In this study the data indicate that oxidants, specifically
nitrating intermediates produced in response to inflammation in
VTE, result in nitration of fibrinogen. The levels of nitrated
fibrinogen were significantly elevated in patients with acute
VTE compared to those negative for the disease. This increase
was not dependent on changes in fibrinogen, as mean levels of
fibrinogen were similar between the two groups. Based on
Fig. 1. Fibrinogen, nitrated fibrinogen, and D-dimer levels in VTE-negative and VTE-positive patients. (A) Plasma fibrinogen levels were measured by two methods: ELISA,
which measures fibrinogen antigen (VTE positive (þVTE), n 49, 5.5 mg/ml, 95% CI 4.9–6.2; VTE negative (VTE), n 194, 5.0 mg/ml, 95% CI 4.7–5.3), and Clauss assay,
which measures fibrin clotting time (þVTE, n 44, 4.3 mg/ml, 95% CI 3.6–4.9; VTE, n 185, 4.0 mg/ml, 95% CI 3.8–4.2). Mean fibrinogen levels for each assay were
compared by Mann–Whitney U test, Pwas nonsignificant for both comparisons. (B) Nitrated fibrinogen levels measured by ELISA were elevated in þVTE (n 48) compared
to VTE (n 178) patients (62.7 nM, 95% CI 56.6–68.8 vs 54.2 nM, 95% CI 51.4–57.1). Nitrated fibrinogen levels were compared by Mann–Whitney U test, *Po0.01.
(C) Spearman’s rank correlation analysis was used to evaluate the relationship between nitrated fibrinogen and Clauss-measured fibrinogen levels (n 207, r 0.31, 95% CI
0.18–0.40; Po0.0001). (D) D-dimer levels measured by Vidas D-dimer exclusion assay were higher in þVTE (n 42) versus VTE (n 157) patients (4.22 mg/ml, 95% CI
3.23–5.20 vs 1.42 mg/ml, 95% CI 1.20–1.63). D-dimer levels were compared by Mann–Whitney U test, **Po0.001. Data for (A), (B), and (D) are represented by box and
whisker plots in which the midline in the box is the median, the bottom and top of the box represent the 25th and 75th percentiles, respectively, and lower and upper bars
represent the 5th and 95th percentiles, respectively.
Fig. 2. Relationship between the odds ratio (OR) of acute VTE and nitrated
fibrinogen levels. A cubic spline regression model of the odds ratio of acute VTE
as a function of nitrated fibrinogen after adjustment for comorbidity, demo-
graphics, and risk factors is shown (n 226). Dotted lines represent the 95% CI.
Po0.005.
previous studies, the levels of nitrated fibrinogen in VTE negative
patients are higher than would be expected in healthy nonsmok
ing controls [14,15]. This is probably due to the presence of
inflammatory and oxidative conditions in the VTE negative popu
lation, including CAD and smoking, which are associated with
increased plasma concentration of nitrated fibrinogen [14 16].
Elevated levels of nitrated fibrinogen in VTE, CAD, and smokers
suggest that inflammation and the production of nitric oxide
derived oxidants are present in thrombotic disorders as well as in
those at risk for the disease. Previous research on the functional
effects of nitration on fibrinogen indicates that this modification
contributes to a prothrombotic phenotype [14 16]. Thus, nitrated
fibrinogen may serve as a comprehensive marker for activation of
inflammatory pathways during thrombosis. Increasing nitrated
fibrinogen levels were positively associated with risk of VTE.
Compared with patients in the lowest quartile of nitrated fibrino
gen, those in the highest quartile had a significantly increased risk
of VTE. This relationship persisted after adjusting individually for
the risk factors that were elevated in the VTE positive group:
advanced age, active cancer, and recent surgery. However, this
risk was not maintained after adjusting for the combined factors.
The relatively small VTE positive patient group may account for
this difference, whereby adjustment reduces the positive group
sample size and eliminates statistical significance. A larger study
would be needed to address this. The loss of significance in our
multivariate regression analysis may also suggest that patients
with more than one of these risk factors also have elevated
nitrated fibrinogen levels independent of VTE. Earlier work has
shown that nitrated proteins, including nitrated fibrinogen, were
significantly elevated in lung cancer patients [31]. Further studies
investigating nitrated fibrinogen in advanced age, various cancer
types, and surgical patients would be necessary to evaluate these
effects. Advanced age, malignancy, and the postoperative state are
well accepted risk factors for VTE [1,32] and were more prevalent
among VTE positive than among VTE negative subjects in our
study. Other established risk factors were present in similar
proportions among the two groups, possibly owing to the rela
tively small size of our study and the small number of patients
harboring such risk factors.
In this study, nitrated fibrinogen was found to be elevated in
the setting of acute VTE. It remains to be determined whether this
elevation reflects an underlying mediator of VTE pathology or is
merely a transient epiphenomenon of acute thrombosis. Studies
in which nitrated fibrinogen levels are measured in patients at
risk for VTE, as well as in the weeks and months following an
event, are needed to address this question and may provide
valuable information regarding VTE recurrence.
Previous work has revealed that fibrinogen is targeted for
oxidative modifications in vivo and in vitro [14 16,31,33 35].
Tyrosine nitration even in the presence of other oxidized amino
acids was shown to significantly accelerate clot formation and
factor XIII cross linking [14,15,34,35]. Incorporation of nitrated
fibrinogen molecules into fibrin clots was documented by immu
noelectron microscopy and was found to alter clot architecture in
a dose dependent manner [14,15]. Changes in structure were
accompanied by changes in viscoelastic properties and a decrease
in dissolution by the fibrinolytic systems [14,15]. Removal of the
nitrated fibrinogen molecules restored the kinetics of fibrin clot
formation and architecture [15]. These profound effects on fibrin
clot structure were produced by a relatively small fraction of
fibrinogen molecules modified by nitration. Based on previous
data and data reported herein, the yield of nitration represents
1 6% of fibrinogen molecules [15]. Kinetic analysis of fibrin
formation revealed that insertion of nitrated fibrinogen molecules
accelerated lateral aggregation, an event that follows the initial
nucleation and the formation of half staggered, double stranded
protofibrils [36 38]. This acceleration is probably due to
increased ‘‘B knob:b hole’’ interactions, which are facilitated by
the site specific nitration of two tyrosine residues near the b hole
of the b chain [15]. Overall, the concept that 1 nitrated molecule
per 100 normal fibrinogen molecules can initiate the catalytic
increase in lateral aggregation is intriguing and consistent with
observations of other proteins that require nucleation events to
form protein fibers [39]. These previous studies suggest that the
elevated levels of nitrated fibrinogen in VTE positive patients
would result in an increase in the kinetics of clot formation and
subsequent changes in clot architecture. Additional studies are
necessary to address this hypothesis.
In addition to nitrated fibrinogen, D dimer levels were sig
nificantly elevated in VTE positive patients consistent with pre
vious studies [19,22 25]. Sensitivity and specificity for D dimer at
a 0.5 mg/ml cutoff in this patient population were 100% (95% CI
91.6 100) and 22.3% (95% CI 16.1 29.6), respectively, and are
similar to what has been previously reported for the Vidas
D dimer exclusion assay [19,25,40].
Fibrinogen is an independent risk factor and predictor of CAD
and associated morbidity and mortality [41,42]. However, its role
in VTE remains unclear. The Leiden Thrombophilia Study (LETS)
showed elevated fibrinogen levels measured by Clauss assay in
DVT patients compared with healthy controls [43]. However, in
later investigations within LETS, increased risk of DVT with
increasing fibrinogen levels was found only in patients 445 years
of age. In patients o45 years, fibrinogen levels in the 95th
percentile did not confer increased risk of DVT [44]. Furthermore,
Table 2
Odds ratio of VTE by quartiles of nitrated fibrinogen.
Quartile
1 2 3 4
Nitrated fibrinogen o43.5 43.5–54.1 54.1–69.6 Z69.7
VTE 50 47 42 39
þVTE 7 9 14 18
Event rate 12.3% 16.1% 25.0% 31.6%
Unadjusted OR 1 1.37 (0.47–3.97) 2.38 (0.88–6.44) 3.30 (1.25–8.68)n
Adjusted OR (1) 1 1.30 (0.44–3.81) 2.22 (0.81–6.08) 3.25 (1.23–8.64)n
Adjusted OR (2) 1 1.37 (0.47–4.02) 2.42 (0.88–6.62) 2.84 (1.06–7.62)n
Adjusted OR (3) 1 1.26 (0.43–3.71) 2.23 (0.82–6.11) 2.84 (1.06–7.62)n
Adjusted OR (4) 1 1.21 (0.40–3.62) 2.17 (0.78–6.03) 2.55 (0.92–7.01)
Values listed as OR (95% CI). Models: 1, adjusted for age; 2, adjusted for cancer; 3, adjusted for surgery; 4, adjusted for age,
cancer, surgery. Odds ratios were compared by Fisher’s exact test.
n Po0.05.
in two separate studies in patients with suspected PE, the levels of
fibrinogen were significantly lower in patients diagnosed as
positive versus negative for the disease [45,46]. In this study,
fibrinogen levels were similar between VTE positive and VTE
negative groups, and there were no differences in DVT versus PE
patients. Patient population or sample size may account for the
differences between this study and LETS, in which DVT patients
were compared to a large number of healthy age and sex
matched controls. Likewise, patient population may also explain
the dissimilarity between this study and the two previous studies
investigating fibrinogen in PE [45,46].
Overall, fibrinogen nitration in VTE patients certainly reflects
active inflammatory and oxidative states that could favor a
procoagulant environment resulting in fibrin structures with
altered biochemical and biophysical properties. These alterations
in fibrin clots may profoundly influence the pathology of VTE.
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